NASDAQ:ALEC Alector Q3 2023 Earnings Report $3.21 -0.10 (-3.02%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$1.56 -1.65 (-51.25%) As of 09:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Alector EPS ResultsActual EPS-$0.53Consensus EPS -$0.65Beat/MissBeat by +$0.12One Year Ago EPSN/AAlector Revenue ResultsActual Revenue$9.11 millionExpected Revenue$9.00 millionBeat/MissBeat by +$110.00 thousandYoY Revenue GrowthN/AAlector Announcement DetailsQuarterQ3 2023Date11/7/2023TimeN/AConference Call DateTuesday, November 7, 2023Conference Call Time4:00PM ETUpcoming EarningsAlector's Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Alector Earnings HeadlinesAlector, Inc.: Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update4 hours ago | finanznachrichten.deGSK halts dementia study after trial results; moves ahead with inhaler4 hours ago | lse.co.ukAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.October 22 at 2:00 AM | Porter & Company (Ad)Alector discontinues extension portion of INFRONT-3 trialOctober 21 at 12:52 AM | msn.comAlector stock plummets after Phase 3 trial failure in FTD treatmentOctober 21 at 7:51 PM | in.investing.comAlector to Reduce Workforce by 49%; R&D Chief ResignsOctober 21 at 7:51 PM | marketwatch.comSee More Alector Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email. Email Address About AlectorAlector (NASDAQ:ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia. The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies. Alector designs its molecules to engage key immune receptors in the brain, seeking to slow or halt disease progression rather than simply address symptoms. Research and development activities are supported by state-of-the-art laboratories in North America and collaborations with academic and industry partners in Europe. Since completing its initial public offering in 2019, Alector has expanded its clinical footprint through strategic alliances and investigator-initiated trials. The company maintains global development programs aimed at bringing the first approved immuno-neurology therapies to patients worldwide. Alector is led by co-founder and Chief Executive Officer Dr. Arnon Rosenthal, a neuroscientist with over two decades of experience in immunology and drug discovery. The management team brings extensive backgrounds in clinical development, regulatory affairs, and commercialization, supporting Alector’s mission to transform the treatment landscape for neurodegenerative diseases.View Alector ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 Earnings Upcoming Earnings Intel (10/23/2025)Honeywell International (10/23/2025)T-Mobile US (10/23/2025)Lloyds Banking Group (10/23/2025)Vale (10/23/2025)Freeport-McMoRan (10/23/2025)Newmont (10/23/2025)Blackstone (10/23/2025)Digital Realty Trust (10/23/2025)Union Pacific (10/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
